News for Eupraxia Pharmaceuticals Inc. (EPRX.TO)

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (”œEupraxia” or the ”œCompany”) (TSX: EPRX) ( EPRX), a clini

**media[643820]**

**media[627670,627671]**

**media[617953]**

Eupraxia Pharmaceuticals (EPRX) reports a Q1 2025 net loss of $6.8 million, compared to $6.2 million in Q1 2024. The company maintains a strong cash pos

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months af

VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (”œEupraxia” or the ”œCompany”) (EPRX) (TSX:EPRX), a clinic

PR NewswireVICTORIA, BC, March 20, 2025 VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPR

PR NewswireVICTORIA, BC, Feb. 25, 2025 Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increa

PR NewswireVICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the roleVICTORIA, BC, Feb. 18, 2025 /PRNewswi

PR NewswireVICTORIA, BC, Nov. 20, 2024 DiffuSphereâ„¢ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues,

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Corcept Therapeutics (CORT), a pharmaceutical company specializing in hormone regulation therapies, experienced a significant stock movement with a 5.04% drop i

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals reports to SEC on latest developments

Eupraxia Pharmaceuticals files report with SEC

New York-based Treasure Global Inc. (TGL) is up over 189 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.